From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
Trade namesNeiromidin
SynonymsAmiridine; NIK-247
ATC code
Legal status
Legal status
  • US: Unscheduled Not FDA approved
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.201.385 Edit this at Wikidata
Chemical and physical data
Molar mass188.27 g/mol g·mol−1
3D model (JSmol)

Ipidacrine (Neiromidin) is a drug first synthesized by the National Research Center for Biologically Active Compounds in the Russian Federation. This compound is a ring-constricted derivative of tacrine (Cognex).[1]

Ipidacrine is a reversible acetylcholinesterase inhibitor used in memory disorders of different origins.[2][3][4]

Ipidacrine directly stimulates impulse transmission in the central nervous system and neuromuscular synapses by blocking membrane potassium channels. Ipidacrine enhances not only choline, but also adrenaline, serotonin, histamine, and oxytocin effects on smooth muscle.[5]


  1. ^ Kojima, Jun; Onodera, Kenji; Ozeki, Mitsuo; Nakayama, Kunio (1998). "Ipidacrine (NIK-247): A Review of Multiple Mechanisms as an Antidementia Agent". CNS Drug Reviews. 4 (3): 247. doi:10.1111/j.1527-3458.1998.tb00067.x.
  2. ^ Damulin, IV; Stepkina, DA; Lokshina, AB (2011). "Neuromidin in mixed vascular and Alzheimer's dementia". Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 111 (2): 40–3. PMID 21350422.
  3. ^ Pustokhanova, LV; Morozova, EM (2011). "Cognitive disorders in the early rehabilitation period of ischemic stroke and possibilities of their treatment with neuromidin". Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 111 (4 Pt 2): 23–7. PMID 23120773.
  4. ^ Onodera, K; Kojima, J; Wachi, M (1998). "Ipidacrine (NIK-247), a novel antidementia, rapidly enters the brain and improves scopolamine-induced amnesia in rats during the Morris water maze task". Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology. 18 (2): 33–7. PMID 9656230.
  5. ^ Neiromidin Product Information